How Investors Are Reacting To Merck (XTRA:MRK) Raised 2026 Outlook
How Investors Are Reacting To Merck (XTRA:MRK) Raised 2026 Outlook Simply Wall St
Covered in this story
Analyst targets on Merck & Co.
- Freedom Broker: at $149 · target $140 by Nov 2027 via Investing.com Canada
- Cantor Fitzgerald: at $148 · target $155 by Nov 2027 · Neutral via MarketBeat
- Guggenheim: at $150 · target $171 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 34 stories mentioning Merck & Co., the earliest published 7 Apr 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.